Inhibikase Raises $50M Through Stock Sale to RA Capital
Inhibikase Therapeutics (IKT) announced a stock sale of 25 million shares to RA Capital Management, raising gross proceeds of $50 million. The company plans to use the funds along with existing cash reserves to support operations until key data from its Phase 3 clinical trial is released.
Topics: at-the-market offering capital raise clinical trial funding